Ontology highlight
ABSTRACT:
SUBMITTER: Anastas JN
PROVIDER: S-EPMC4071371 | biostudies-literature | 2014 Jul
REPOSITORIES: biostudies-literature
Anastas Jamie N JN Kulikauskas Rima M RM Tamir Tigist T Rizos Helen H Long Georgina V GV von Euw Erika M EM Yang Pei-Tzu PT Chen Hsiao-Wang HW Haydu Lauren L Toroni Rachel A RA Lucero Olivia M OM Chien Andy J AJ Moon Randall T RT
The Journal of clinical investigation 20140527 7
About half of all melanomas harbor a mutation that results in a constitutively active BRAF kinase mutant (BRAF(V600E/K)) that can be selectively inhibited by targeted BRAF inhibitors (BRAFis). While patients treated with BRAFis initially exhibit measurable clinical improvement, the majority of patients eventually develop drug resistance and relapse. Here, we observed marked elevation of WNT5A in a subset of tumors from patients exhibiting disease progression on BRAFi therapy. WNT5A transcript an ...[more]